Latest Hotspot

Japan sanctions VYLOY™ (zolbetuximab) by Astellas as a new therapeutic for stomach cancer management

1 April 2024
3 min read

Astellas Pharma Inc. revealed that the Japanese Ministry of Health, Labour and Welfare has sanctioned the use of VYLOY™ (zolbetuximab), a therapeutic agent targeting anti-claudin 18.2 (CLDN18.2) for the treatment of individuals diagnosed with advanced, inoperable, or metastatic stomach cancer that tests positive for CLDN18.2. This marks the inaugural authorization worldwide of a CLDN18.2-specific medical treatment by a health regulatory body.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Stomach cancer often goes unnoticed until it reaches later stages or begins spreading due to initial symptoms that are easily confused with more commonplace gastrointestinal issues. In 2022, Japan recorded 126,724 new cases, making it the nation's third most lethal form of cancer.

Dr. Moitreyee Chatterjee-Kishore, holding the position of Senior Vice President and directing Immuno-Oncology Development at Astellas, commented, "Receiving the green light from the MHLW for VYLOY is a milestone in managing stomach cancer, representing the singular personalized treatment approach for those afflicted with CLDN18.2-positive gastric cancer. Astellas is committed to fulfilling the dire need for an effective therapeutic approach for this aggressive cancer, especially prominent in Japan."

The Lead Researcher of the SPOTLIGHT Trial, Dr. Kohei Shitara, MD, emphasized, "With a scarce selection of specific treatments for late-stage gastric adenocarcinoma, pioneering new treatments is imperative. The findings support the use of VYLOY as a promising therapy for the CLDN18.2-positive demographic in Japan, which saw nearly 44,000 deaths due to this type of cancer in the year 2022."

In their quest to battle this disease, Astellas has joined forces with Roche Diagnostics to endorse the VENTANA CLDN18 RxDx Assay, a tailored immunohistochemistry test designed to find patients who could benefit from treatment with VYLOY. The test is initially available through several central labs in Japan, with expectations to broaden its availability as time progresses.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of March 28, 2024, there are 146 investigational drugs for the CLDN18.2 target, including 69 indications, 139 R&D institutions involved, with related clinical trials reaching 44, and as many as 2743 patents.

Zolbetuximab's approval, target specificity, and therapeutic potential position it as a promising drug in the field of biomedicine. Further research and development, as well as market expansion efforts, could contribute to its success in addressing the needs of patients with various cancers and digestive system disorders.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Global New Drug Research and Development Progress Weekly Report(3.25-3.31)
Drug Highlight
18 min read
Global New Drug Research and Development Progress Weekly Report(3.25-3.31)
1 April 2024
Curated Selection of the Latest Developments in the Field of New Drug Research and Development: A Quick Overview of Progress in New Drug R&D, Pharmaceutical Deals, and Cutting-Edge Technologies from This Week.
Read →
FDA Approves First and Only Once-Daily Single-Pill Combination Therapy for Pulmonary Arterial Hypertension
Hot Spotlight
10 min read
FDA Approves First and Only Once-Daily Single-Pill Combination Therapy for Pulmonary Arterial Hypertension
29 March 2024
On March 22, Johnson & Johnson announced FDA approval of OPSYNVI®, their new drug for treating WHO Group 1 PAH and class II-III PAH in adults. OPSYNVI® combines macitentan and tadalafil in a single tablet.
Read →
Phase II Trial Begins for ABY-025 PET Diagnostic in Gastric and Esophageal Cancers
Latest Hotspot
3 min read
Phase II Trial Begins for ABY-025 PET Diagnostic in Gastric and Esophageal Cancers
29 March 2024
Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.
Read →
Corteria Pharmaceuticals Initiates Phase 1 Trial for Heart Failure Drug COR-1167
Latest Hotspot
3 min read
Corteria Pharmaceuticals Initiates Phase 1 Trial for Heart Failure Drug COR-1167
29 March 2024
Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.